Glucotrack Secures Waivers From Warrant Holders, Issues 406,198 New 5-Year Warrants at $7.50

Glucotrack (GCTK) agreed to issue 406,198 new 5-year warrants at $7.50 to certain warrant holders, lifting issuance restrictions and waiving anti-dilution adjustments. The move aims to facilitate near-term financing, pending stockholder approval for share issuance under Nasdaq rules.

Original reporting
Published Oct 19, 2026, 8:13 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 19, 2026, 8:22 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Glucotrack Secures Waivers From Warrant Holders, Issues 406,198 New 5-Year Warrants at $7.50 — source image
Decision brief

The 30-second read

$GCTKBearishLow
01

Why it matters

The waiver and new warrant issuance aim to clear obstacles for near‑term financing, but increase potential share dilution.

02

Market read

Primary disclosure of a corporate action that could modestly depress the stock due to dilution risk.

03

What to watch

The 9.99% ownership cap and floor price tied to 20% of issuance‑date price may limit dilution severity.

Relevance 5/10Novelty 6/10Timing: post‑market filing on Oct 19

Background

Glucotrack is a clinical‑stage biotech that previously faced anti‑dilution concerns from existing warrant holders.

Company-level read

Ticker impact

$GCTKBearishMedium confidence
Context

Glucotrack filed an 8‑K announcing a Waiver Agreement and the issuance of 406,198 new 5‑year warrants at $7.50 each.

Expected impact

likely downward pressure as the market prices in dilution risk

Evidence & confidence

Warrant issuance without immediate capital raise signals future share issuance, which typically weighs on share price.

Market effects

May affect other small‑cap biotech and specialty pharma stocks as investors reassess dilution risk.

Limited to U.S. micro‑cap market; no broader regional effect.

Minimal global impact.

Counterpoint

If the capital raise succeeds, the infusion could boost cash and offset dilution concerns, supporting upside.

Key entities

  • Glucotrack, Inc.

    Issuer of the new warrants.

  • Existing warrant holders

    Counterparties to the waiver agreement.

Related articles

$GCTKHigh

On July 14, 2026, Glucotrack, Inc., a Delaware corporation, entered into an Agreement and Plan of Merger with Glucotrack Merger Sub, Inc., a Nevada…

Glucotrack, Inc. (GCTK) filed an SEC Form 8-K — Other Events. Exhibit 99.1 unaudited pro forma financial information On July 14, 2026 (the “Closing Date”), Glucotrack, Inc., a Delaware corporation (“Glucotrack”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Glucotrack Merger Sub, Inc., a Nevada corporation (“Me

$GCTKMed

GCTK Stock Jumps As Qare Data Platform Launch Fuels Momentum

GlucoTrack Inc. (GCTK) stock surged 14.04% on October 28, 2026, driven by the launch of its Qare data platform. The company's stock has seen significant volatility, trading at $1.95 after a 380% increase from its low. GlucoTrack reported a quarterly net loss of $3.8M and negative free cash flow. The Qare platform, focused on GLP-1 medications, aims to collect and compare patient data, potentially attracting partnerships. The company also expanded its ai² platform globally.

$GCTKMed

Lōkahi plans one shot per visit instead of 15 for honeybee-venom treatment

Lōkahi Therapeutics, a subsidiary of Glucotrack (GCTK), has initiated GMP manufacturing for LT-100, a honeybee-venom-derived biologic for osteoarthritis pain. The company aims to transition from 15 intradermal injections to a single subcutaneous injection per visit. GMP production is a key step in advancing LT-100 through clinical and regulatory milestones, with the first patient enrollment expected later this year, according to the company.

$GLUCMed

Glucotrack Secures $5.5 Million Financing to Support Growth Strategy and Product Development

Glucotrack Inc. said it raised about $5.5 million through institutional financing, including a $2.0 million equity investment priced at $0.75 per unit (share plus 5-year warrant at $1.50) and $3.5 million in follow-on convertible debt. The company plans to use proceeds to fund its implantable continuous blood glucose monitoring program and biopharmaceutical platform via Lōkahi Therapeutics.